Withdrawal Syndrome Clinical Trial
Official title:
Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses: Randomized Controlled Trial.
The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the
incidence is estimated at 32.1%.
Cerebrospatized patients are probably more prone to withdrawal because they require high
doses of sedation.
Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of
the therapeutic management).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04422808 -
AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)
|
||
| Not yet recruiting |
NCT05512091 -
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use
|
||
| Recruiting |
NCT05883358 -
Kratom Use Disorder Management Using Clonidine and/or Buprenorphine
|
||
| Completed |
NCT03573479 -
Early Rehabilitation in Critically Ill Children - The PICU Liber8 Study
|
||
| Completed |
NCT03018977 -
Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT
|
N/A | |
| Completed |
NCT05336656 -
Assessment of Analgesics and Sedatives in Mechanically Ventilated Patients With COVID-19
|
||
| Terminated |
NCT03645603 -
Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)
|
Phase 2 | |
| Completed |
NCT03996096 -
Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.
|